Should I buy or sell Jasper Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares. View JSPR analyst ratings or view top-rated stocks .

What is Jasper Therapeutics' stock price target for 2024?

5 brokerages have issued 12-month price objectives for Jasper Therapeutics' shares. Their JSPR share price targets range from $40.00 to $70.00. On average, they predict the company's stock price to reach $59.63 in the next twelve months. This suggests a possible upside of 239.0% from the stock's current price. View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts .

How have JSPR shares performed in 2024?

Jasper Therapeutics' stock was trading at $7.89 at the beginning of the year. Since then, JSPR shares have increased by 122.9% and is now trading at $17.59. View the best growth stocks for 2024 here .

When is Jasper Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our JSPR earnings forecast .

When did Jasper Therapeutics' stock split?

Shares of Jasper Therapeutics reverse split on the morning of Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Fernwood Investment Management LLC (4.43%), Monaco Asset Management SAM (2.24%), Ieq Capital LLC (0.49%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Anna Louise French, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans, Velan Capital Investment Manag and William Lis. View institutional ownership trends .

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:JSPR

Jasper Therapeutics (JSPR) Stock Price, News & Analysis

$17.59

+0.23 (+1.32%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $16.23
▼
$17.90
50-Day Range: $4.24
▼
$17.59
52-Week Range: $4.00
▼
$21.90

Volume: 82,100 shs
Average Volume: 137,285 shs
Market Capitalization: $196.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $59.63

Get Jasper Therapeutics alerts:

Jasper Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 239.0% Upside
$59.63 Price Target
Short Interest: Healthy
2.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.17
Based on 10 Articles This Week
Insider Trading: Acquiring Shares
$4.54 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($6.16) to ($6.46) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

408th out of 922 stocks

Biotechnology Industry

7th out of 24 stocks

3.5

Analyst's Opinion

Consensus Rating
Jasper Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $59.63, Jasper Therapeutics has a forecasted upside of 239.0% from its current price of $17.59.
Amount of Analyst Coverage
Jasper Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.38% of the float of Jasper Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Jasper Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Jasper Therapeutics has recently increased by 4.45%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Jasper Therapeutics does not currently pay a dividend.
Dividend Growth
Jasper Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JSPR.

3.4

News and Social Media Coverage

News Sentiment
Jasper Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Jasper Therapeutics this week, compared to 1 article on an average week.
Search Interest
15 people have searched for JSPR on MarketBeat in the last 30 days. This is an increase of 114% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jasper Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,544,800.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.90% of the stock of Jasper Therapeutics is held by insiders.
Percentage Held by Institutions
79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Jasper Therapeutics are expected to decrease in the coming year, from ($6.16) to ($6.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jasper Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jasper Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Jasper Therapeutics has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Jasper Therapeutics Stock (NASDAQ:JSPR)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

JSPR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JSPR Stock News Headlines

February 10, 2024 | americanbankingnews.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Major Shareholder Velan Capital Investment Manag Purchases 350,000 Shares of Stock

February 7, 2024 | msn.com

Jasper Therapeutics Announces Offering Pricing Details

February 12, 2024 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

February 7, 2024 | msn.com

Jasper Therapeutics Launches $50M Share Offering

February 7, 2024 | finance.yahoo.com

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

February 6, 2024 | marketwatch.com

Jasper Therapeutics Shares Rise 20% After Offering Prices

February 6, 2024 | finance.yahoo.com

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

February 5, 2024 | finance.yahoo.com

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

January 24, 2024 | finance.yahoo.com

Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why

January 23, 2024 | ca.finance.yahoo.com

JSPR Feb 2024 10.000 call

January 6, 2024 | finanznachrichten.de

Jasper Therapeutics, Inc.: Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

January 5, 2024 | finance.yahoo.com

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

January 2, 2024 | msn.com

Jasper Therapeutics to effect 1-for-10 reverse stock split

January 2, 2024 | finance.yahoo.com

Jasper Therapeutics, Inc. Announces Reverse Stock Split

December 10, 2023 | finance.yahoo.com

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

November 30, 2023 | finanznachrichten.de

Jasper Therapeutics: Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

November 30, 2023 | finance.yahoo.com

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

November 9, 2023 | msn.com

Jasper Therapeutics GAAP EPS of -$0.16 in-line

November 9, 2023 | benzinga.com

Jasper Therapeutics: Q3 Earnings Insights

November 9, 2023 | finance.yahoo.com

Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress

November 9, 2023 | finance.yahoo.com

Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023 | finance.yahoo.com

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

November 2, 2023 | finance.yahoo.com

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

November 1, 2023 | finance.yahoo.com

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

October 23, 2023 | thestreet.com

Jasper Therapeutics Inc.

October 10, 2023 | finance.yahoo.com

Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) high institutional ownership speaks for itself as stock continues to impress, up 25% over last week

See More Headlines

Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 2/12/2024
Next Earnings (Estimated): 3/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:JSPR
CUSIP: N/A
CIK: 1788028
Web: jaspertherapeutics.com
Phone: 650-549-1400
Fax: N/A
Employees: 35
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $59.63
High Stock Price Target: $70.00
Low Stock Price Target: $40.00
Potential Upside/Downside: +239.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,690,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -66.86%
Return on Assets: -57.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.84
Quick Ratio: 8.84

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.46 per share
Price / Book: 1.86

Miscellaneous

Outstanding Shares: 11,160,000
Free Float: 10,723,000
Market Cap: $196.30 million
Optionable: Optionable
Beta: 1.98

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Ronald A. Martell (Age 62)
President, CEO & Director
Comp: $892.45k
Dr. Judith Anne Shizuru M.D. (Age 68)
Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
Comp: $291.25k
Mr. Jeetinder Singh Mahal M.B.A. (Age 52)
Chief Operating Officer
Comp: $579.46k
Mr. Herbert C. Cross (Age 52)
CFO & Corporate Secretary
Dr. Luca Di Noto Ph.D.
Senior Vice President of Technical Operations
Mr. David Ku M.D.
Vice President of Corporate Development, Portfolio Strategy & Management
Mr. Matthew Ford
Vice President of Human Resources
Dr. Wendy Pang M.D.
Ph.D., Senior Vice President of Research & Translational Medicine
Dr. Edwin Jonathan Tucker M.D. (Age 52)
Chief Medical Officer
Ms. Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JSPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Jasper Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JSPR shares.
View JSPR analyst ratings or view top-rated stocks.
What is Jasper Therapeutics' stock price target for 2024?: 5 brokerages have issued 12-month price objectives for Jasper Therapeutics' shares. Their JSPR share price targets range from $40.00 to $70.00. On average, they predict the company's stock price to reach $59.63 in the next twelve months. This suggests a possible upside of 239.0% from the stock's current price.
View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts.
How have JSPR shares performed in 2024?: Jasper Therapeutics' stock was trading at $7.89 at the beginning of the year. Since then, JSPR shares have increased by 122.9% and is now trading at $17.59.
View the best growth stocks for 2024 here.
When is Jasper Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024.
View our JSPR earnings forecast.

When did Jasper Therapeutics' stock split?: Shares of Jasper Therapeutics reverse split on the morning of Thursday, January 4th 2024. The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
Who are Jasper Therapeutics' major shareholders?: Jasper Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Fernwood Investment Management LLC (4.43%), Monaco Asset Management SAM (2.24%), Ieq Capital LLC (0.49%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Anna Louise French, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans, Velan Capital Investment Manag and William Lis.
View institutional ownership trends.
How do I buy shares of Jasper Therapeutics?: Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JSPR) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial